静脉血栓治疗药物-利伐沙班

Rivaroxaban (Xarelto) is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban (Xarelto) Indications: 1. Used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. 

The recommended dose is oral rivaroxaban (Xarelto) 10 mg once daily. If the wound has stopped bleeding, the first medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a missed dose occurs, the patient should take rivaroxaban (Xarelto) immediately and continue to take the drug once a day the next day. Patients can take rivaroxaban (Xarelto) with a meal or on its own.

The new anticoagulant drug rivaroxaban (Xarelto) from Bayer Healthcare of Germany can effectively reduce the formation of venous thrombosis in patients after major orthopedic surgery, and its efficacy is better than the current standard therapy of enoxaparin. Statistics show that without preventive treatment, up to 60% of patients may develop venous thrombosis, leading to various malignant consequences including death. According to Bayer, compared with traditional drugs that require injection or continuous monitoring, rivaroxaban (Xarelto) can be taken directly and does not require monitoring, making clinical treatment more convenient.